Earlier this month, the FDA approved the emergency use of a new coronary pneumonia drug called Ridsiewe,media reported. In response, Gilead Sciences, the company that makes the drug, announced that it will donate 1.5 million bottles of Ridsiewe in the next six weeks, 607,000 of which will remain in the U.S. The U.S. Department of Health and Human Services (HHS) said that would be enough to treat 78,000 inpatients.
That may sound like a lot, but according to Bloomberg, more than 300,000 patients in the U.S. are eligible for the drug.
“The initial supply of Redsey may be subject to greater limitations than we previously estimated,” RBC analyst Brian Abrahams said in a note to clients. Initially, the analyst expected 80 per cent of Gilead’s supply to remain in the US, and now it is just over 40 per cent. In addition, the first two batches shipped fewer than 50,000 bottles, meaning the first rollout will be slower than expected.
Of these, New York is the state most in need of treatment. Of the 1.3 million cases in the United States, more than 300,000 occurred in New York State. Earlier this week, HHS shipped 565 boxes of Ridsewe — 40 vials per box — to New York, more than any other state received. However, new City’s mayor, Bill de Blasio, still gets only 10 percent of what is needed.
“We remain at the centre of this crisis. So I hope that the White House will heed our request and provide us with the additional dose we need quickly. Beth Howe said at his daily news conference on Sunday.